Themis Bioscience, an Austrian biotech company, has started a phase 1 trial for its vaccine candidate MV-LASV against Lassa fever, through the first administration to healthy volunteers, it was reported yesterday.
The company is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fever vaccine candidate.
The phase 1 trial for the product is a randomised, placebo-controlled, dose-finding study that will have 60 healthy adult participants. The early-stage clinical trial is being conducted by the Centre for the Evaluation of Vaccination in Antwerp, Belgium. It will evaluate the safety, tolerability and immunogenicity of MV-LASV after administration of two different dose levels.
The vaccine programme is funded by a global partnership forged by Themis with CEPI that will support the development of the MV-LASV vaccine candidate until the end of phase 2.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine